Product/Composition:- | Tenofovir AF + Emtricitabine + Bictegravir |
---|---|
Strength:- | Bictegravir-50 mg + Emtricitabine-200 mg + TAF-25 mg |
Form:- | Tablet |
Reference Brands:- | Biktarvy(EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Biktarvy is a once-daily, complete HIV-1 treatment with Bictegravir, Emtricitabine, and TAF. FDA and EMA approved, it offers high resistance protection and improved kidney and bone safety—no booster required.
Biktarvy is a complete, once-daily antiretroviral therapy for HIV-1 infection, combining Bictegravir 50 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide (TAF) 25 mg in a single tablet. Approved by both the FDA and EMA, Biktarvy is indicated for adults and pediatric patients (≥2 years, ≥14 kg) who are treatment-naïve or virologically suppressed. Bictegravir, a potent integrase inhibitor, offers a high barrier to resistance and does not require boosting agents. TAF enhances renal and bone safety over older TDF-based regimens. Biktarvy simplifies HIV management, supporting long-term viral suppression and patient adherence through convenient once-daily dosing, with or without food.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications